Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes.
The associate professor of hematology spoke with CancerNetwork®about frontline treatments available for patients with chronic lymphocytic leukemia and the toxicities present for these treatments.
An international systematic review and meta-analysis indicated that stereotactic body radiation therapy compared to conventionally fractioned radiation therapy with concurrent chemotherapy may offer a modest improvement in OS with a more favorable toxicity profile.
The FDA granted orphan drug designation to umbralisib based on results from the phase IIb UNITY-NHL trial cohort of patients with follicular lymphoma who have received at least 2 prior lines of therapy, including an anti-CD20 monoclonal antibody and an alkylating agent.
After a serious adverse reaction to a clinical trial put her in critical condition, Barbara Bigelow now shows no signs of breast cancer and is no longer on any cancer medications.
The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.
The goal of the study is to determine the effect of adagloxad simolenin administered with the potent adjuvant OBI-821 as a therapeutic vaccine treatment on improving invasive disease-free survival in the study population.
Aditya Bardia, MD, MPH detailed the clinical development of antibody drug conjugates in patients with metastatic triple negative breast cancer, as well as what to expect moving forward with antibody drug conjugates in the metastatic breast cancer space.
As more agents become approved, it’s important to individualize therapy for this patient population, Sara A. Hurvitz, MD, said at the 37th Annual Miami Breast Cancer Conference.
The study found that 31 to 60 days seems to be the ideal time period to begin adjuvant chemotherapy in HER2-positive breast cancer patients.